Navigation Links
Par Pharmaceutical Companies Reports Fourth Quarter and Full-Year Results for 2010
Date:2/24/2011

enses:Research and development

12,91219,66850,36939,235Selling, general and administrative

52,10242,752192,504165,135Settlements and loss contingencies, net

5,4563,5603,762307Restructuring costs

-(246)-1,006Total operating expenses

70,47065,734246,635205,683Gain on sale of product rights and other

25-6,0253,200Operating income

24,82325,604132,921131,470Gain on bargain purchase

---3,021Loss on extinguishment of senior subordinated convertible notes

-(4,962)-(2,598)(Loss) gain on marketable securities and other investments, net

(108)-3,459(55)Interest income

3153301,2572,658Interest expense

(151)(1,078)(2,905)(8,013)Income from continuing operations before provision
for income taxes

24,87919,894134,732126,483Provision for income taxes

7,2499,05041,98048,883Income from continuing operations

17,63010,84492,75277,600Discontinued operations:Provision for income taxes

12614421672Loss from discontinued operations

(126)(144)(21)(672)Net income

$17,504$10,700$92,731$76,928Basic earnings (loss) per share of common stock:Income from continuing operations

$0.50$0.32$2.70$2.30Loss from discontinued operations

(0.00)(0.00)(0.00)(0.02)Net income

$0.50$0.32$2.70$2.28Diluted earnings (loss) per share of common stock:Income from continuing operations

$0.48$0.31$2.60$2.27Loss from discontinued operations

(0.00)(0.00)(0.00)(0.02)Net income

$0.48$0.31$2.60$2.25Weighted average number of common shares outstanding:  Basic

34,87833,77334,30733,679  Diluted

36,34534,96435,64434,188PAR PHARMACEUTICAL COMPANIES, INC.CONSOLIDATED BALANCE SHEETSDECEMBER 31, 2010 AND 2009(In Thousands, Except Share Data)December 31,December 31,20102009ASSETSCurrent assets:Cash and cash equivalents$218,674$121,668Available for sale marketable debt securities27,86639,525Accounts receivable, net  95,705154,837Inventori
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015  A recent study ... Knee Journal, compared the Arthrosurface HemiCAP® Wave implant, ... versus an "onlay" design implant for isolated patellofemoral ... in function and pain scores, none of the ... osteoarthritis (OA). However, 53% of the patients in ...
(Date:8/27/2015)... , Aug. 27, 2015 Biosimilars ... (BPC) applauds the U.S. Food and Drug Administration ... distinguishable name in its draft guidance issued today. ... biological products proposes distinguishable names, calling for biological ... an FDA-designated suffix. This proposal reflects the agency,s ...
(Date:8/27/2015)... -- According to a new market research report "Medical ... Bariatric ), Material (Nylon, Padded, Canvas), Usage Type (Disposable, Reusable), End ... the Medical Lifting Sling Market is poised to reach USD 706.0 ... CAGR of 11.4 % from 2015 to 2020. ... T ables and 65 F ...
Breaking Medicine Technology:Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4
... 2011 Reportlinker.com announces that a new market ... Gastric Cancer - Global Drug Forecasts ... 2011 http://www.reportlinker.com/p0479813/Gastric-Cancer---Global-Drug-Forecasts-and-Treatment-Analysis-to-2020-–-Volume-I-2011.html ... Treatment Analysis to 2020 – Volume I 2011 ...
... April 12, 2011 Reportlinker.com announces that a new ... Bladder Cancer - Global Drug Forecasts and ... http://www.reportlinker.com/p0479812/Bladder-Cancer---Global-Drug-Forecasts-and-Treatment-Analysis-to-2020---Volume-1-2011.html Bladder Cancer ... - Volume 1 2011 Summary ...
Cached Medicine Technology:Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 2Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 3Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 4Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 5Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 6Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 7Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 8Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 9Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 10Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 11Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 12Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 13Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 14Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 15Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 16Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 17Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 18Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 19Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 20Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 21Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 22Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 2Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 3Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 4Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 5Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 6Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 7Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 8Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 9Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 10Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 11Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 12Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 13Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 14Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 15
(Date:8/29/2015)... ... August 29, 2015 , ... "I have been a licensed ... "I specialize in manual therapy, and my invention will provide headache sufferers a ... additional muscle dysfunction throughout the body." , They developed THE RELIEVER to alleviates ...
(Date:8/29/2015)... ... August 29, 2015 , ... Brands like Toppik , ... standard shipping costs. , “Before, a threshold of $49.00 was required to qualify for ... items qualify for free standard shipping for customers regardless of the item’s selling price.” ...
(Date:8/29/2015)... ... August 29, 2015 , ... Hamstring ... area with stretching, soft tissue manipulation. Platelet rich plasma injections also have ... research to improve treatment outcomes. This localized treatment seems to address the ...
(Date:8/28/2015)... ... 28, 2015 , ... Joining a growing number of hospitals ... management companies to partner with Wound Care Advantage (WCA) to utilize the ... , Transitioning wound care management providers can be a complex undertaking. WCA provides ...
(Date:8/28/2015)... ... August 28, 2015 , ... An article published August 19th by ... has gone through to open a pizzeria in Westchester. Mr. LaRocco was aware from ... several months, but the current process, having already gone on for over a year, ...
Breaking Medicine News(10 mins):Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2
... youths surveyed aren,t smoking to get high, , , FRIDAY, April ... just for recreation but to self-medicate emotional problems, sleep difficulties ... interviews with 63 adolescents who smoked marijuana regularly. About a ... a medication rather than as a means of getting high. ...
... Researchers from the Children,s Cancer Hospital at The University ... how to turn off a certain receptor that promotes ... presented today in a platform session at the 22nd ... (ASPHO). , "There is a certain receptor we now ...
... NORCROSS, Ga., April 24 Immucor, Inc. (Nasdaq: ... instrument-reagent systems to the blood transfusion industry, today announced ... Department of Justice, Antitrust Division, requesting documents for the ... to an investigation of possible violations of the federal ...
... half of all deaths stem from treatable conditions, study ... or treatable health conditions account for nearly 70 percent ... whites in the United States, a new study shows. ... than 65 are caused by preventable or treatable conditions ...
... Message of Hope Considered ,Too Important Not To Be ... announced today that "Light of Hope: Help for Children ... recovery, will debut internationally on Friday, April 24, Saturday, ... www.findingthewords.org during the final week of World ...
... Actions Implemented During 2008 Position the Company for Future, ... Exchange: NVC,VANCOUVER, April 24 /PRNewswire-FirstCall/ - Neovasc Inc. (TSXV: ... December 31, 2008. , "The fundamental changes Neovasc implemented ... we believe they have resulted in a lean and ...
Cached Medicine News:Health News:Marijuana Is Option to Unpleasant Meds, Teens Say 2Health News:Researchers find drug that inhibits acute leukemia cell growth 2Health News:Racial Disparity in Death Rate May Be Avoidable 2Health News:'Light of Hope: Help for Children with Autism' Ground-Breaking Internet Television Event on April 24 to April 26 Co-Sponsored by Internet Software Leaders 2Health News:'Light of Hope: Help for Children with Autism' Ground-Breaking Internet Television Event on April 24 to April 26 Co-Sponsored by Internet Software Leaders 3Health News:Neovasc Inc. Reports Year 2008 Financial Results 2Health News:Neovasc Inc. Reports Year 2008 Financial Results 3Health News:Neovasc Inc. Reports Year 2008 Financial Results 4Health News:Neovasc Inc. Reports Year 2008 Financial Results 5Health News:Neovasc Inc. Reports Year 2008 Financial Results 6Health News:Neovasc Inc. Reports Year 2008 Financial Results 7Health News:Neovasc Inc. Reports Year 2008 Financial Results 8Health News:Neovasc Inc. Reports Year 2008 Financial Results 9Health News:Neovasc Inc. Reports Year 2008 Financial Results 10Health News:Neovasc Inc. Reports Year 2008 Financial Results 11Health News:Neovasc Inc. Reports Year 2008 Financial Results 12Health News:Neovasc Inc. Reports Year 2008 Financial Results 13
... Agilis Steerable Introducer helps physicians ... right or left atrium. With ... tip, and radiopaque tip marker, ... the agility and stability needed ...
... 70 RF Generator introduces maximum ... every day, in every ablation ... and the CARTO EP Navigation ... Catheter provide clinicians with a ...
The Microny pacemakers are among the smallest devices in the world. The Microny II SR+ pacemaker is the world's smallest, single-chamber rate-responsive pulse generator. The Microny pacemakers featur...
... family of pacemakers features several ... truly automatic devices in today's ... unparalleled combination of automated features ... builds on the popular and ...
Medicine Products: